In another study, Irbesartan treatment significantly reduced levels of the tubular marker urinary KIM-1 in patients with type 2 diabetes and microalbuminuria, indicating the role of KIM-1 in monitoring treatment effect in DN [43]. Here, HAVCR1 is linked to liver dysplastic nodule.